{"id":6821,"date":"2026-05-19T16:23:20","date_gmt":"2026-05-19T14:23:20","guid":{"rendered":"https:\/\/www.institut-biotherapies.fr\/?p=6821"},"modified":"2026-05-21T11:21:36","modified_gmt":"2026-05-21T09:21:36","slug":"asgct-2026-genethon-presents-results-from-three-gene-therapy-programs-in-clinical-development","status":"publish","type":"post","link":"https:\/\/www.institut-biotherapies.fr\/en\/2026\/05\/19\/asgct-2026-genethon-presents-results-from-three-gene-therapy-programs-in-clinical-development\/","title":{"rendered":"ASGCT 2026: Genethon presents results from three gene therapy programs in clinical development"},"content":{"rendered":"<div class=\"chapo\">\n<p>At ASGCT 2026 in Boston, Genethon presented new clinical data from three of its gene therapy programs in Duchenne muscular dystrophy, gamma-sarcoglycanopathy (LGMD-R5), and Crigler-Najjar syndrome. In total, Genethon teams presented 8 oral presentations and 13 posters.<\/p>\n<\/div>\n<div>\n<div id=\"formatted_text_24308\" class=\"paragraph paragraph--formatted-text\">\n<div class=\"paragraph-content\">\n<p data-end=\"733\" data-start=\"440\">Genethon, the French laboratory dedicated to the research and development of gene therapies for rare diseases created by AFM-Telethon, presented several clinical results at the annual meeting of the American Society of Gene &amp; Cell Therapy (ASGCT), held from May 11 to 15, 2026, in Boston, USA.<\/p>\n<p data-end=\"880\" data-start=\"735\">Genethon teams presented a total of 8 oral presentations and 13 posters covering several gene therapy programs currently in clinical development.<\/p>\n<p><a href=\"https:\/\/www.afm-telethon.fr\/en\/news\/asgct-2026-genethon-presents-results-three-gene-therapy-programs-clinical-development\">Read more<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>At ASGCT 2026 in Boston, Genethon presented new clinical data from three of its gene therapy programs in Duchenne muscular dystrophy, gamma-sarcoglycanopathy (LGMD-R5), and Crigler-Najjar syndrome. In total, Genethon teams presented 8 oral presentations and 13 posters. Genethon, the French laboratory dedicated to the research and development of gene therapies for rare diseases created by &hellip; <a href=\"https:\/\/www.institut-biotherapies.fr\/en\/2026\/05\/19\/asgct-2026-genethon-presents-results-from-three-gene-therapy-programs-in-clinical-development\/\">[Read more]<\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-6821","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/comments?post=6821"}],"version-history":[{"count":2,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6821\/revisions"}],"predecessor-version":[{"id":6838,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/posts\/6821\/revisions\/6838"}],"wp:attachment":[{"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/media?parent=6821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/categories?post=6821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.institut-biotherapies.fr\/en\/wp-json\/wp\/v2\/tags?post=6821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}